|
|
|
|
||
Re: ESMO2022 Presidential Symposium for Phase 3 COSMIC-313 on 12Sep2022Date Mon, 12.09.2022 Time 16:30 - 18:15 Location 6.P - Paris Auditorium Chairs
Session Type Proffered Paper session LBA8 - Phase 3 study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)Presentation Number LBA8 Speakers
Lecture Time 16:30 - 16:45 Invited Discussant LBA8Speakers
Lecture Time 16:45 - 16:55 LBA9 - Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: first results of the RADICALS-HD trial (ISRCTN40814031)Presentation Number LBA9 Speakers
Lecture Time 16:55 - 17:10 Invited Discussant LBA9Lecture Time 17:10 - 17:20 LBA11 - IPSOS: Results from a Phase 3 study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimenPresentation Number LBA11 Speakers
Lecture Time 17:20 - 17:35 Invited Discussant LBA11Speakers
Lecture Time 17:35 - 17:45 Q&A and discussionLecture Time 17:45 - 18:05 |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
29081 | Re: ESMO2022 Presidential Symposium for Phase 3 COSMIC-313 on 12Sep2022 | JoeFlow | 2 | 8/19/2022 11:14:45 AM |